Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	Tirzepatide Mounjaro Sign up to track	MOTS-c Mitochondrial ORF of the 12S rRNA-c Sign up to track
Evidence Grade	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence
Regulatory	FDA ApprovedFDA ApprovedApproved by the US Food and Drug Administration for at least one indication	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Category	Metabolic & Weight Loss	Metabolic & Weight Loss
Key Benefits	•Superior weight loss compared to semaglutide (average 20-25%) •Effective diabetes management •Improves insulin sensitivity •Cardiovascular protection +2 more	•Improves insulin sensitivity •Enhances exercise capacity and endurance •Metabolic regulation and longevity •Increases NAD+ levels +3 more
Dosage	2.5-15 mg mg	5-10 mg mg
Frequency	Once weekly	2-3x per week
Administration	Subcutaneous	SubcutaneousIntramuscular
Mechanism	Tirzepatide is a novel dual GIP/GLP-1 receptor agonist. It is the first medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. FDA-approved for type 2 diabetes and weight management.	MOTS-c is a mitochondrial-derived peptide that acts as a mitochondrial signaling molecule. It regulates metabolic homeostasis and has been called an 'exercise mimetic' due to its effects on metabolism and exercise capacity.
Side Effects / Risks	Not specified	Not specified
Research Status	FDA-approved for diabetes (Mounjaro) and weight management (Zepbound)	Research compound with growing scientific interest